Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease
- PMID: 36777996
- PMCID: PMC9903716
- DOI: 10.1016/j.xgen.2022.100192
Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease
Abstract
Biobanks facilitate genome-wide association studies (GWASs), which have mapped genomic loci across a range of human diseases and traits. However, most biobanks are primarily composed of individuals of European ancestry. We introduce the Global Biobank Meta-analysis Initiative (GBMI)-a collaborative network of 23 biobanks from 4 continents representing more than 2.2 million consented individuals with genetic data linked to electronic health records. GBMI meta-analyzes summary statistics from GWASs generated using harmonized genotypes and phenotypes from member biobanks for 14 exemplar diseases and endpoints. This strategy validates that GWASs conducted in diverse biobanks can be integrated despite heterogeneity in case definitions, recruitment strategies, and baseline characteristics. This collaborative effort improves GWAS power for diseases, benefits understudied diseases, and improves risk prediction while also enabling the nomination of disease genes and drug candidates by incorporating gene and protein expression data and providing insight into the underlying biology of human diseases and traits.
Keywords: GWAS; ancestry diversity; biobank; genetic association studies; meta-analysis; phenotype harmonization.
© 2022.
Conflict of interest statement
M.J.D. is a founder of Maze Therapeutics. B.M.N. is a member of the scientific advisory board at Deep Genomics and a consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. The spouse of C.J.W. works at Regeneron Pharmaceuticals. C.-Y.C. is employed by Biogen. C.R.G. owns stock in 23andMe, Inc. T.R.G. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. E.E.K. has received speaker fees from Regeneron, Illumina, and 23andMe and is a member of the advisory board for Galateo Bio. R.E.M. has received speaker fees from Illumina and is a scientific advisor to the Epigenetic Clock Development Foundation. G.D.S. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. K.S. and U.T. are employed by deCODE Genetics/Amgen, Inc. J.Z. has received research funding from various pharmaceutical companies to support the application of Mendelian randomization to drug target prioritization. S.M. is a co-founder of and holds stock in Seonix Bio.
Figures






References
-
- Fatumo S., Mugisha J., Soremekun O.S., Kalungi A., Mayanja R., Kintu C., Makanga R., Kakande A., Abaasa A., Asiki G., et al. Uganda Genome Resource: a rich research database for genomic studies of communicable and non-communicable diseases in Africa. bioRxiv. 2022 doi: 10.1101/2022.05.05.22274740. Preprint at. Published online May 7. - DOI - PMC - PubMed
Grants and funding
- R56 HG012354/HG/NHGRI NIH HHS/United States
- R01 HL109946/HL/NHLBI NIH HHS/United States
- 212946/Z/18/Z/WT_/Wellcome Trust/United Kingdom
- R01 DK062370/DK/NIDDK NIH HHS/United States
- MC_PC_14135/MRC_/Medical Research Council/United Kingdom
- IK2 CX001780/CX/CSRD VA/United States
- MC_UU_00017/1/MRC_/Medical Research Council/United Kingdom
- K99 HG012222/HG/NHGRI NIH HHS/United States
- MC_UU_00011/4/MRC_/Medical Research Council/United Kingdom
- P30 DK020572/DK/NIDDK NIH HHS/United States
- MC_PC_13049/MRC_/Medical Research Council/United Kingdom
- MC_UU_00007/10/MRC_/Medical Research Council/United Kingdom
- MC_U137686851/MRC_/Medical Research Council/United Kingdom
- 210561/Z/18/Z/WT_/Wellcome Trust/United Kingdom
- MC_UU_00011/1/MRC_/Medical Research Council/United Kingdom
- T32 HG000040/HG/NHGRI NIH HHS/United States
- MC_UU_12026/2/MRC_/Medical Research Council/United Kingdom